EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually. The lecanemab data and additional research findings from Eis

Related Keywords

Tabeta ,Mie ,Japan ,China ,United Kingdom ,Canada ,Great Britain ,Robert Perneczky ,Sysmex Eisai ,Jeffrey Cummings ,Miia Kivipelto ,Lynn Kramer ,Bioarctic Eisai ,Ministry Of Health ,Alzheimer Clinical Trial Consortium ,National Institutes Of Health ,Asset In Development ,Washington University School Of Medicine ,Critical Path For Alzheimer Disease Consortium ,National Institute On ,Ad Cooperative Study ,Biomarkers In Predicting Amyloid Positivity Community ,Drug Administration ,Eisai Inc ,Clinical Research At Eisai Inc ,Alzheimer Network Trials Unit ,Shimadzu Oita University Eisai ,Deputy Chief Clinical Officer ,Senior Vice President ,Clinical Research ,Chief Clinical Officer ,Key Compounds ,Central European Time ,Targeting Therapies ,Neuropsychiatric Consequences ,Poster Number ,Performance Evaluation Of Plasma ,Critical Path ,Clinical Dementia Rating Sum ,Daily Living Scale ,Mild Cognitive Impairment ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Binding Profiles ,Different Forms ,Amyloid Beta Might Explain Efficacy ,Side Effects ,Clinical Trials ,Early Alzheimer ,New England Journal ,Alzheimer 39s Disease ,D ,Presentation ,Meaningful Benefits ,Disai ,